Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Trial Title: Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

NCT ID: NCT06001151

Condition: Carcinoma, Non-Small-Cell Lung

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Carboplatin
Pemetrexed

Conditions: Keywords:
non-squamous Non-Small Cell Lung Cancer
Programmed Cell Death Ligand 1
cadonilimab

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Cadonilimab
Description: Patients receive cadonilimab (10mg/kg) every 3 weeks.
Arm group label: Experimental Arm

Other name: AK104

Intervention type: Drug
Intervention name: Pemetrexed
Description: Patients receive pemetrexed (500mg/m2) every 3 weeks.
Arm group label: Experimental Arm

Intervention type: Drug
Intervention name: Carboplatin
Description: Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
Arm group label: Experimental Arm

Summary: This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

Detailed description: This trial enrolled advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative. Patients will receive cadonilimab (10mg/kg) plus pemetrexed(500mg/m2) and carboplatin (AUC=5) every 3 weeks for 4 cycles, follwed with cadonilimab (10mg/kg) plus pemetrexed (500mg/m2) every 3 weeks as maintenance therapy. The primary endpoint is 12-month progression-free-survival (PFS) rate assessed by investigators. Key secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression free survival (PFS), overall survival (OS), and safety.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patients with histologically/cytologically stage IIIB, IIIC, IV non-squamous Non-Small Cell Lung Cancer (NSCLC) - PD-L1 TPS<1% - Life expectancy more than 3 months - Without EGFR-sensitive mutation (19Exon del/21Exon L858R), ALK, ROS1 gene rearrangement or fusion - Has no prior systemic therapy; (chemotherapy and/or radiotherapy is allowed as part of neoadjuvant/adjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant/adjuvant treatment would be enrolled) - ECOG score 0-1 - Patients must have at least one measurable lesion according to RECIST 1.1 - Has adequate organ function - Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing) - Voluntarily sign a written informed consent form Exclusion Criteria: - Histological examination with Small Cell Lung Cancer or squamous Non-Small Cell Lung Cancer - With active central nervous system (CNS) metastases confirmed by CT or MRI - With other malignancy within 3 years before enrollment - With severe infections within 4 weeks of the first dose of study treatment - Women who are pregnant or lactating - History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia requiring hormone therapy - History of myocarditis, cardiomyopathy, and malignant arrhythmia - Tumor compresses important surrounding organs (such as the esophagus) with accompanying symptoms, compressing the superior vena cava or invading the mediastinal vessels, heart, etc. - Risk of bleeding, major hemoptysis, or with history of coagulation dysfunction - Active autoimmune diseases that require systematic treatment within 2 years before enrollment - History of Human Immunodeficiency Virus (HIV) - With active hepatitis B infection - With uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Qian Chu

Address:
City: Wuhan
Zip: 430030
Country: China

Status: Recruiting

Contact:
Last name: Qian Chu

Phone: 13212760751

Phone ext: +86
Email: qianchu@tjh.tjmu.edu.cn

Start date: August 7, 2023

Completion date: August 31, 2027

Lead sponsor:
Agency: Qian Chu
Agency class: Other

Collaborator:
Agency: Akeso Pharmaceuticals, Inc.
Agency class: Other

Source: Tongji Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06001151